The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of clinical pharmacology

• Publication date

  2016-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/jcph.769PMID 27196064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenomics and Clopidogrel

  2017cited by this paper
• Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans

  2015cited by this paper
• Non‐antiplatelet effect of clopidogrel: improving endothelial function in Chinese healthy subjects with different CYP2C19 genotype

  2015cited by this paper
• Platelet Function Tests: Why They Fail to Guide Personalized Antithrombotic Medication

  2015cited by this paper
• Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn!

  2015cited by this paper
• Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy: Systematic Review

  2015cited by this paper
• High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization: A Landmark Analysis of the ARCTIC Study

  2014cited by this paper
• Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes

  2014cited by this paper
• Precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy.

  2014cited by this paper
• Mechanisms of plaque formation and rupture.

  2014cited by this paper
• A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users

  2014cited by this paper
• Proton pump inhibitor use represents an independent risk factor for myocardial infarction.

  2014cited by this paper
• Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel

  2014cited by this paper
• Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.

  2014cited by this paper
• Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

  2013cited by this paper
• Platelet function and genetic testing.

  2013cited by this paper
• Personalized antiplatelet therapy: the wrong approach?

  2013cited by this paper
• Proton Pump Inhibitors and Potential Interactions with Clopidogrel: An Update

  2013cited by this paper
• Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping

  2013cited by this paper
• Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.

  2013cited by this paper
• Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: Risk of coronary events and peptic ulcer bleeding

  2013cited by this paper
• Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation.

  2013cited by this paper
• No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis.

  2013cited by this paper
• In vitro biotransformation studies of 2-oxo-clopidogrel: multiple thiolactone ring-opening pathways further attenuate prodrug activation.

  2013cited by this paper
• One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study

  2012cited by this paper
• Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review

  2012cited by this paper
• CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events

  2012cited by this paper
• Antiplatelet Therapy and Proton Pump Inhibition: Clinician Update

  2012cited by this paper
• Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.

  2012cited by this paper
• Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer.

  2012cited by this paper
• Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature

  2012cited by this paper
• Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?

  2012cited by this paper
• A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel.

  2012cited by this paper
• Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events

  2012cited by this paper
• Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring.

  2012cited by this paper
• Antiplatelet therapy and proton pump inhibition: cause for concern?

  2012cited by this paper
• Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel

  2012cited by this paper
• Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin

  2012cited by this paper
• Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement

  2011cited by this paper
• Paraoxonase-1 is a major determinant of clopidogrel efficacy

  2011cited by this paper
• CYP2C19 genotype and proton pump inhibitors in clopidogrel-treated patients: does it take two to tango?

  2011cited by this paper
• Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy.

  2011cited by this paper
• Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.

  2011cited by this paper
• Proton pump inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm?

  2011cited by this paper
• CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

  2011cited by this paper
• Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry

  2011cited by this paper
• Pharmacogenomics and clopidogrel: irrational exuberance?

  2011cited by this paper
• Review article: proton pump inhibitors with clopidogrel – evidence for and against a clinically‐important interaction

  2011cited by this paper
• Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement.

  2010cited by this paper
• ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

  2010cited by this paper
• Clopidogrel and endothelial injury after percutaneous coronary interventions: beyond the antiplatelet effects.

  2010cited by this paper
• Usefulness of clopidogrel to protect against diabetes-induced vascular damage.

  2010cited by this paper
• The potential interaction between clopidogrel and proton pump inhibitors: a systematic review

  2010cited by this paper
• The case for routine genotyping in dual-antiplatelet therapy.

  2010cited by this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cited by this paper
• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials

  2010cited by this paper
• ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

  2010cited by this paper
• Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use

  2010cited by this paper
• Meta‐analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

  2010cited by this paper
• Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention

  2010cited by this paper
• Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.

  2010cited by this paper
• Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

  2009cited by this paper
• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

  2009cited by this paper
• Genetic determinants of response to clopidogrel and cardiovascular events.

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Risk of combining PPIs with thienopyridines: fact or fiction?

  2009cited by this paper
• Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel.

  2009cited by this paper
• Cytochrome P-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• Proton pump inhibitors and clopidogrel: putting the interaction in perspective.

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

  2008cited by this paper
• Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

  2008cited by this paper
• Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.

  2008cited by this paper
• Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Mechanism of hydrolysis and aminolysis of homocysteine thiolactone.

  2006cited by this paper
• Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease: Evidence for Antioxidant and Antiinflammatory Effects

  2006cited by this paper
• Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol

  2006cited by this paper
• The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

  2006cited by this paper
• Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin

  2006cited by this paper
• A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite

  2005cited by this paper
• The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

  2003cited by this paper
• Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial

  2003cited by this paper
• Structure and stereochemistry of the active metabolite of clopidogrel.

  2002cited by this paper
• Identification and Biological Activity of the Active Metabolite of Clopidogrel

  2000cited by this paper
• Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P 450 2 C 19 * 2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

  year unknowncited by this paper

• The role of genomics and proteomics in drug discovery and its application in pharmacy

  2025cites this paper
• Drug Transporters and Metabolizing Enzymes in Antimicrobial Drug Pharmacokinetics: Mechanisms, Drug–Drug Interactions, and Clinical Implications

  2025cites this paper
• The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study.

  2024cites this paper
• Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH

  2024cites this paper
• CYP3A4 and CYP2C19 genetic polymorphisms and myricetin interaction on tofacitinib metabolism.

  2024cites this paper
• In Vitro Analysis of AKR1D1 Interactions with Clopidogrel: Effects on Enzyme Activity and Gene Expression

  2024cites this paper
• Suspected clopidogrel-associated hepatitis in a cat

  2024cites this paper
• Applications of Nanozymes in Chiral-Molecule Recognition through Electrochemical and Ultraviolet–Visible Analysis

  2024cites this paper
• Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes

  2023cites this paper
• Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies

  2023cites this paper
• Prodrugs: Harnessing chemical modifications for improved therapeutics

  2023cites this paper
• Comprehensive Investigation of the Influence of High-Altitude Hypoxia on Clopidogrel Metabolism and Gut Microbiota.

  2023cites this paper
• Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review

  2022cites this paper
• An Albumin-Enriched Nanocomplex Achieves Systemic Delivery of Clopidogrel Bisulfate to Ameliorate Renal Ischemia Reperfusion Injury in Rats.

  2022cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Interaction study of Salvianolic acids for injection on pharmacokinetics of clopidogrel in rats by LC-MS/MS.

  2022cites this paper
• Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review

  2022cites this paper
• Quantitative estimation of intra-subject variability in bioequivalence studies of generic solid oral dosage forms by multiple regression analysis

  2021cites this paper
• Microglia and Neuroinflammation: What Place for P2RY12?

  2021cites this paper
• Cannabis Drug Interactions

  2021cites this paper
• Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis

  2020cites this paper
• Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists

  2020cites this paper
• CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants

  2020cites this paper
• Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients

  2020cites this paper
• Association of Frailty With Antiplatelet Response Among Elderly Chinese Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

  2020cites this paper
• Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial

  2020cites this paper
• Effect of herbs for treating coronary heart disease on the CYP450 enzyme system and transporters.

  2020cites this paper
• Effectiveness of Platelet Function Analysis-Guided Aspirin and/or Clopidogrel Therapy in Preventing Secondary Stroke: A Systematic Review and Meta-Analysis

  2020cites this paper
• Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke

  2020cites this paper
• PON-1 Q 192 R ( rs 662 ) Gene Polymorphism and The Risk of Major Adverse Cardiovascular Events in Clopidogrel-Treated Patients with Coronary Heart Disease : A Systematic Review and Meta-Analysis

  2019cites this paper
• Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.

  2019cites this paper
• Adenosine and the Cardiovascular System

  2019cites this paper
• Farmacogenética del clopidogrel en pacientes sometidos a neurointervención percutánea

  2019influential citation
• A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents

  2019cites this paper
• CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel

  2018cites this paper
• Exploring PTDH–P450BM3 Variants for the Synthesis of Drug Metabolites

  2018cites this paper
• Effect of clopidogrel and atorvastatin on hemorheology , inflammatory reaction and blood coagulation in patients with cerebral infarction

  2018cites this paper
• Late-Stage Aromatic C-H Oxygenation.

  2018cites this paper
• Development and validation of a sensitive and rapid UHPLC–MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma

  2018cites this paper
• CYP‐Mediated Drug–Drug Interaction Is Not a Major Determinant of Attenuation of Antiplatelet Function of Clopidogrel by Vonoprazan

  2018cites this paper
• The Herb-Drug Interaction of Clopidogrel and Xuesaitong Dispersible Tablet by Modulation of the Pharmacodynamics and Liver Carboxylesterase 1A Metabolism

  2018cites this paper
• Assessment of clopidogrel discontinuation rates following pharmacogenomic testing in a high-risk patient population : an interim analysis of the UPGRADE Registry

  2017cites this paper
• Management of Blood Loss in Hip Arthroplasty: Korean Hip Society Current Consensus

  2017cites this paper
• Clopidogrel in a combined therapy with anticancer drugs—effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models

  2017cites this paper